Heterozygous Familial Hypercholesterolaemia clinical trials

Explore recruiting heterozygous familial hypercholesterolaemia clinical trials.

Recruiting heterozygous familial hypercholesterolaemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heterozygous Familial Hypercholesterolaemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia

Slovakia, Bulgaria, Spain, Finland, Sweden, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Reassessment of statin-associated musscle symptoms in adults with familial hypercholesterolemia: A phase IV randomized double-blinded n-of-1 crossover trial including periods with atorvastatin, placebo and no study treatment

Norway

Therapeutic use (Phase IV) EU CTIS Study details

An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who have completed the adolescent ORION-16 or ORION-13 studies (VICTORION-PEDS-OLE)

Germany, Spain, Hungary, Norway, Netherlands, Poland +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Study 1002-041: An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) with Heterozygous Familial Hypercholesterolemia

Germany, Netherlands, Denmark, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Heterozygous Familial Hypercholesterolaemia trials by city

Heterozygous Familial Hypercholesterolaemia in Toronto Heterozygous Familial Hypercholesterolaemia in Vancouver Heterozygous Familial Hypercholesterolaemia in Montreal Heterozygous Familial Hypercholesterolaemia in Calgary Heterozygous Familial Hypercholesterolaemia in Edmonton Heterozygous Familial Hypercholesterolaemia in Ottawa Heterozygous Familial Hypercholesterolaemia in Winnipeg Heterozygous Familial Hypercholesterolaemia in Quebec City Heterozygous Familial Hypercholesterolaemia in Hamilton Heterozygous Familial Hypercholesterolaemia in Kitchener Heterozygous Familial Hypercholesterolaemia in London Heterozygous Familial Hypercholesterolaemia in Halifax Heterozygous Familial Hypercholesterolaemia in New York Heterozygous Familial Hypercholesterolaemia in Los Angeles Heterozygous Familial Hypercholesterolaemia in Chicago Heterozygous Familial Hypercholesterolaemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease